ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishBYD Electronics
14 Jan 2024 05:22

Index Rebalance & ETF Flow Recap: HSI, LQ45, FXI, 2823 HK, SENSEX

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
901 Views
Share
08 Jan 2024 09:00

Hong Kong Connect Flows (December): Six Months of Inflows

We analyzed the Hong Kong Connect Scheme for December and highlight flows for Meituan, CNOOC, PICC P&C, China Mobile, Tencent, Xiaomi, HKEx, Wuxi...

Logo
440 Views
Share
bearishWuxi Biologics
08 Jan 2024 05:10

FXI Rebalance Preview: Two Potential Changes in March

There could be 2 changes for the FXI in March with CGN Power and Yankuang Energy replacing CR Beer and Wuxi Bio. Impact on the potential adds is...

Logo
574 Views
Share
05 Jan 2024 10:43

Hong Kong Buybacks Weekly (Jan 5th): Tencent, AIA, Xiaomi

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
970 Views
Share
x